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Abstract
We describe the initial results of a neonatal screening program for four lysosomal storage diseases (MPS I, Pompe,
Gaucher and Fabry) using the digital microfluidics methodology. The method successfully identified patients previ-
ously diagnosed with these diseases and was used to test dried blood spot samples obtained from 10,527 newborns
aged 2 to 14 days. The digital microfluidic technology shows potential for a simple, rapid and high-throughput screen-
ing for these four diseases in a standard neonatal screening laboratory.
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Neonatal screening for lysosomal storage diseases
(LSDs) has been gaining considerable interest as a result of
the new policies to promote early diagnosis of rare diseases,
the development of new screening methods, and the avail-
ability of enzyme replacement and other specific therapies
for several LSDs. Also, LSDs are not considered too rare
anymore, with a combined incidence for the around 50
LSDs estimated to be around 1/7,000 (Meikle et al., 1999;
Poorthuis et al., 1999).
LSDs have a wide spectrum of clinical signs and
symptoms, with overlapping findings across different dis-
eases and with most disorders presenting large variability
(Gieselmann, 2005). This makes the diagnosis particularly
difficult, especially as it needs to be confirmed with sophis-
ticated biochemical and genetic tools (Wang et al., 2011).
For these reasons there is often a delay in the diagnosis of
LSDs (Vieira et al., 2008). This delay may influence the
outcome of treatment, already available for several of these
conditions (Giugliani et al., 2016).
The development of high-throughput protocols with
multiplexing capabilities for use with dried blood spot
(DBS) samples has facilitated the establishment of NBS
programs for LSDs around the world (Spada et al., 2006;
Hwu et al., 2009; Hopkins et al., 2015).
We present here the initial results obtained with a
fluorimetric digital microfluidics (DMF) platform used for
the neonatal screening of four LSDs [Mucopolysacchari-
dosis I (MPS I), Gaucher, Fabry, and Pompe diseases].
A DMF platform was used to assay the activities of
-L- iduronidase (IDUA), to screen for MPS I; acid -glu-
cosidase (GAA), to screen for Pompe; acid -glucosidase
(GBA), to screen for Gaucher; and acid -galactosidase
(GLA), to screen for Fabry in the newborn’s samples.
We used one workstation with four digital micro-
fluidic instruments to run a multiplexed fluorometric enzy-
matic assay platform as described previously (Sista et al.,
2011; Sista et al., 2013). All necessary hardware and re-
agents for GAA, GBA, GLA, and IDUA were supplied by
Baebies Inc (Durham, NC, USA).
DBS samples from patients previously diagnosed
with MPS I, Gaucher, Pompe or Fabry diseases were ini-
tially tested to check the capability of the method in identi-
fying the respective enzyme deficiencies (Table 1).
DBS samples were then collected from 10,527 new-
borns aged 2 to 14 days of life, randomly selected for test-
ing among the cards routinely received by the Neonatal
Screening Center, based in Porto Alegre, Brazil. Samples
from newborns were spotted on the filter paper and shipped
Genetics and Molecular Biology, 41, 2, 414-416 (2018)
Copyright © 2018, Sociedade Brasileira de Genética. Printed in Brazil
DOI: http://dx.doi.org/10.1590/1678-4685-GMB-2017-0227
Send correspondence to Roberto Giugliani. Serviço de Genética
Médica, Hospital de Clinicas de Porto Alegre, Rua Ramiro Barcelos
2350, 90035-903 Porto Alegre, RS, Brazil. E-mail:
rgiugliani@hcpa.edu.br.
Short Communication
at room temperature to the reference laboratory, arriving
there within 24 to 72 hours .Tests were performed no more
than 48 hours after sample arrival.
The DMF assay protocol to determine the enzyme ac-
tivity in a multiplex format took less than four hours, allow-
ing three runs per day (eventually, one overnight) and
yielded 152 results in each run (total, 456 per day) when us-
ing one working station with four fluorimeters in parallel.
Overall coefficient of variation (CV) values between car-
tridges, days, instruments, and operators ranged from 4 to
22%. Linearity correlation coefficients were  0.98 for all
assays.
Cutoff values of 5.1 mol/L/h for IDUA,
5.9 mol/L/h for GAA, 3.9 mol/L/h for GBA, and
5.7 mol/L/h for GLA were established during a prelimi-
nary phase using 1,000 samples from the cards routinely
collected and DBS specimens from patients with confirmed
LSDs previously diagnosed. These cut-off values were not
very different from the ones established by Hopkins et al.
(2015), using the same method (4.0, 8.0, 4.5, and
5.5 mol/L/h, respectively).
The method correctly discriminated nine samples of
affected patients (3 from MPS I, 2 from Pompe, 2 from
Gaucher and 2 from Fabry cases) previously diagnosed,
from samples of normal subjects. Further information on
cutoffs and results in known patients is displayed in
Table 1.
Four samples out of the 10,527 tested showed activity
below the cutoff and were further investigated until a final
conclusion was established. These cases were studied by
another group and eventually classified as pseudodeficien-
cy (low activity of enzyme without generation of storage
and with no clinical consequences, usually found in pa-
tients who present mutations already known as related to
pseudodeficiency) of -L-iduronidase carriership for MPS
I (1 case), pseudodeficiency of -glucosidase (1 case) and
carriership for Gaucher disease (1 case) (Bravo et al.,
2017).
The availability of effective therapies for several
LSDs (Aronovich et al., 2015) and the evidence that early
introduction of therapy may bring a better outcome (Ga-
brielli et al., 2016) make neonatal screening for these con-
ditions an option to be considered. This is especially true as
several high-throughput platforms became available to per-
form tests in a large number of samples at a low cost per as-
say (Matern et al., 2015).
In the present report we demonstrated that DMF was
efficient in identifying samples from patients previously di-
agnosed with MPS I, Gaucher, Fabry and Pompe diseases.
Although we cannot discard that false negatives could oc-
cur, this possibility is considered very small, as affected pa-
tients usually have extremely low enzyme activities, and all
affected patients tested were identified by the method in the
validation process (data not shown). The usefulness of this
platform was already reported by Hopkins et al. (2015),
who detected 1/1,618 newborns affected by one of these
four diseases in 43,686 samples evaluated. We identified
four samples among the 10,527 DBS from newborns tested
with a low enzyme activity (1/2,631). Although subsequent
testing informed that these were not true LSDs, all these
cases had true low enzyme activity, which was detected by
the screening program using the DMF method.
This is the first report of neonatal screening for multi-
ple LSDs conducted in Brazil. It is important to mention
that this program was performed in a standard clinical bio-
chemistry laboratory, indicating that, in addition to be effi-
cient and robust, the platform is suitable to less sophisti-
cated laboratories, as are most of the laboratories in Latin
America. The successful use of this strategy to simulta-
neously measure four enzyme activities indicates that this
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Table 1 - Averages for each enzyme activity in normal subjects, cut-off
values and results in confirmed cases previously diagnosed.
MPS-1 Results (mol/L/h)
Samples (n=9864)
IDUA average 17.1
calculated IDUA cut-off (30%) 5.1
Positive samples (n=3)
Patient 1 3.4
Patient 2 4.9
Patient 3 3.7
FABRY Results (mol/L/h)
Samples (n=9988)
GLA average 18.9
calculated GLA cut-off (30%) 5.7
Positive samples (n=2)
Patient 1 4.2
Patient 2 4.7
Patient 3 3.6
POMPE Results (mol/L/h)
Samples (n=9560)
GAA average 19.8
calculated GAA cut-off (30%) 5.9
Positive samples (n=2)
Patient 1 3.4
Patient 2 3.1
GAUCHER Results (mol/L/h)
Samples (n=9878)
GBA average 13
calculated GBA cut-off (30%) 3.9
Positive samples (n-2)
Patient 1 3.3
Patient 2 3.5
method could be an option for Brazil and other developing
countries.
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